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Dendritic cellsAutophagy has a pivotal role in the in-vitromonocyte differentiation into macrophages and dendritic cells (DCs),
the most powerful antigen presenting cells (APC) with the unique capacity to initiate an adaptive immune re-
sponse. Autophagy is also amechanism bywhich these cells of innate immunity may degrade intracellular path-
ogens and mediate the antigen processing and presentation, essential to clear an infection. For these reasons,
pathogens have learned how to manipulate autophagy for their own survival. In this study we found that hepa-
titis C virus (HCV), derived fromsera of infectedpatients, blocked the autophagic process in differentiatingmono-
cytes, seen as LC3 II and p62 expression levels. The suppression of autophagy correlated with a reduction of
cathepsins D, B and proteolytic activity, and resulted in impairment of monocyte differentiation into DCs, as in-
dicated by the reduction of CD1a acquirement. These data suggest that the block of autophagy might be one of
the underlying mechanisms of the HCV-mediated immune subversion that frequently leads to viral persistence
and chronic hepatitis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Human hepatitis C virus (HCV) is a positive-stranded RNA viruswith
size of 50 to 80 nm in diameter, belonging to the Flaviviridae family that
exists in six different genotypes. It is an important cause of morbidity
andmortalityworldwide, since it has been reported that approximately
170 million of people are infected. No vaccinations are at the moment
available and the current therapies are not always efﬁcient to clear the
infection, particularly in patients harboring HCV genotype 1, which is
themost common genotype inWestern Europe [1]. Recently, direct act-
ing anti-viral drugs, HCV speciﬁc protease inhibitors, have been discov-
ered and shown to be much more effective in the eradication of HCV
infection, although they come at a signiﬁcant cost. HCV infects preferen-
tially hepatocytes, causing acute and chronic hepatitis, although it hasDP-ribose polymerase p85 frag-
icrotubule-associated protein 1
gioni),been reported that also B and T cells, monocytes, macrophages,
macrophage-like Kuppfer cells and dendritic cells can be infected in-
vivo and in-vitro [2–4]. The viral persistence in the infected host sug-
gests that HCV is able to manipulate the immune system in order to es-
cape from its control [5–7]; however the underlying molecular
mechanisms are not completely elucidated yet. Progress in understand-
ing HCV biology and the virus–host interaction has remained challeng-
ing due to lack of an efﬁcient cell culture system for viral growth. The
majority of research on this virus, indeed, utilizes sub-genomic or full-
length replicon models that replicate in Huh7 hepatoma cell line or in
their more permissive sublines, instead of natural virus [8,9].
Autophagy, a cellular degradative process, aimed at the removal of
long lived/misfolded proteins as well as damaged organelles, plays an
essential role in regulating cell survival and differentiation [10]. It is
characterized by the presence of autophagosomes, whose formation
can be monitored by many means such as direct electron microscopy
observations as well as western blot analysis, by which the appearance
of the lipidated form of microtubule-associated protein light chain 3
(LC3II) can be detected [11]. Autophagy represents a cellular strategy
that helps cells to survive in stressful conditions, such as during nutrient
shortage or in the course of chemotherapeutic treatments [12–14].
Moreover, in the cells of the immune system, autophagy represents a
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son that pathogens manipulate it in order to escape from the immune
control [16–18]. More recently, it has been reported that autophagy, in-
duced by GM-CSF in in-vitro differentiating monocytes, drives their dif-
ferentiation into DCs [19].
Previous studies, utilizing replicon models, have addressed the im-
pact of HCV on autophagy. They have shown that HCV induces an in-
complete autophagy in Huh7.5 cells, due to the lack of fusion of the
autophagosomes with the lysosomes or, as reported in another study,
that HCV genotype 1b, but not genotype 2a, induces an incomplete au-
tophagy in Huh7 cells, by altering the lysosomal compartment [20,21].
In this study, we investigated whether HCV derived from sera of in-
fected patients would inﬂuence the autophagic process of monocytes
differentiating into DCs.We thought that the natural HCV from infected
patients might represent a useful biological system to mimic the virus–
host interaction in a way that it is more similar to the natural infection.
Replicon HCV models, indeed, seem to have different biological behav-
ior, e.g. they do not generally infect peripheral blood mononuclear
cells while HCV isolated from sera of infected patients is able to do so
[3,22].We focused our study on genotype 1 HCV because it is character-
ized by a lower response to conventional therapy, leading more fre-
quently to chronic infection, and also because this genotype has been
shown to have a higher impact on autophagy [20]. We found that HCV
derived from sera of infected patients mediated an autophagic block
in differentiating monocytes that correlated with reduced expression
level of cathepsins, also accompanied by reduced lysosomal proteolitic
activity. Cathepsins are the main class of lysosomal proteases that play
a fundamental role in the degradation of the autophagic cargo [23].
They are subdivided into three subgroups, according to the aminoacids
of their active sites that confer catalytic activity: that is, cysteine
(cathepsins B, C, F, H, K, L, N, O, S, T, U, W, and X), aspartyl (cathepsins
D and E), and serine cathepsins (cathepsins A and G).
More importantly, we found that the autophagic block, mediated by
HCV-positive sera, resulted in the inhibition ofmonocyte differentiation
into DCs, compared to efﬁcientDCdifferentiation achieved culturing the
same cells with sera derived from healthy donors that did not interfere
with the autophagic process.
DCs, essential for the activation of T cells, are fewer and dysfunction-
al, in the course of HCV chronic infection [24]. On the other hand, in the
low percent of patients that clear the infection, the major role is played
by a robust T cell response, which is strictly dependent on DC activi-
ty [25,26].
Therefore our results suggest that the impairment of the autophagic
process in differentiating monocytes could be one of the mechanisms
throughwhichHCV leads to the inhibition of DC formation, circumvents
its lysosomal degradation and consequently alters the DC-mediated
viral antigen presentation to the T cells, leading to viral persistence,
chronic hepatitis and eventually to hepatocarcinoma.
2. Materials and methods
2.1. Human sera
The experiments were conducted with the understanding and the
consent of each participant, and the responsible ethical committee of
“Policlinico Umberto I” has approved the experiments. Human sera
were obtained from healthy donors (HCV, HIV and HBsAg-negative)
or from HCV-infected patients (HIV and HBsAg-negative), in which
the viral load was measured by VERSANT HCV RNA 3.0 Assay (Siemens
Health Care, Australia; cat. no. 02553870). The limits of detection (LOD)
and quantiﬁcation (LOQ)were 15HCVRNA IU/ml according to the assay
package inserts. Valid results were reported quantitatively (IU/ml), as
“positive b LOQ” (if the value obtainedwas under the LOQ), or as “target
not detectable”.
Genotyping was performed with the Siemens Versant HCV Ampliﬁ-
cation 2.0Kit (LIPA).Sera from3 patients, whichwere anti-IgGHCVpositive, asmeasured
by ELISA (ADVIA Centaur, Siemens Health Care, Australia; cat. no.
03438099) and who had high levels HCV RNA IU/ml of circulating
HCVRNA, (N2 × 106), genotype 1, were used throughout the study. A
human HCV core-positive serum tested by western blot (Inno-LIA,
Innogenetics, Belgium, Europe; cat. no. 80538) was used to detect HCV
core protein.
In some experiments, the HCV-positive sera were ultraﬁltered with
30 k Vivaspin columns (Sartorius, Goettingen, Germany, Europe cat.
No. VS01S1). This ultraﬁltration process, validated for removal of a vari-
ety of enveloped and non-enveloped viruses with size from 70 nm to 30
nm, was used to remove HCV particles.
2.2. Antibodies and reagents
The following antibodies were used: mouse monoclonal anti-Cd1a
(BD Pharmingen, San Jose, California, USA; cat. no. 558703), rabbit poly-
clonal anti-LC3I/II (Novus Biologicals, Cambridge, UK; cat. no. NB100-
2220SS), mouse monoclonal anti-p62 (BD Transduction Laboratories,
San Jose, California, USA; cat. no. 6108333), goat polyclonal anti-
cathepsin D (Santa Cruz Biotechnology, Europe; cat. no. sc-6487) and
mouse monoclonal anti cathepsin S (Santa Cruz Biotechnology,
Europe; cat. no. sc-271573), mouse monoclonal anti-cathepsin B
(Abcam, Cambridge, MA, USA; cat. no. ab58802), rabbit polyclonal
anti-cleaved PARP (poly-ADP-ribose polymerase p85 fragment)
(Promega, Madison, WI, USA; cat. no. G7341), mouse monoclonal anti-
b actin (Sigma, St. Louis, USA; cat. no. A2228) and mouse monoclonal
anti-tubulin (Santa Cruz Biotechnology, Europe; cat. no. sc-8035).
DQ Red BSA (Molecular Probes) was purchased from Life Technolo-
gies (Life Technologies, Monza, Italy, Europe; cat. no. D-12051);
baﬁlomycin A1 (20 nM) (Sigma, St. Louis, USA; cat. no B1793) and
rapamycin (1 mM) (Sigma, St. Louis, USA; cat. no. R8781) were pur-
chased from Sigma. Cathepsin D inhibitor (pepstatin A) was purchased
from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Europe; cat.
no. sc-43036) and cathepsin B inhibitor (Inhibitor III) was purchased
from Calbiochem (Calbiochem, MA, USA; cat. no. 219419).
2.3. Generation of monocyte-derived DC
To generate monocyte-derived DC, human peripheral blood mono-
nuclear cells, obtained from healthy donors were isolated by Ficoll-
Paque gradient centrifugation (Pharmacia, Uppsala, Sweden) from
buffy coats. CD14+ monocytes were positively selected using anti-
CD14 MAb-conjugated magnetic microbeads (Miltenyi Biotec, Auburn,
CA, USA; cat. no. 130-050-201). Puriﬁed monocytes (more than 95%
CD14+, as evaluated by FACS analysis) were cultured at a density of
1 × 106 cells/3 ml in 12-well plates for 6 days in the differentiating cock-
tail: RPMI 1640 (Sigma, St. Louis, MO, USA; cat. no. R0883) containing
10% FCS (Euroclone, Milan, Italy; cat. no. ECLS0180L, 2 mM L-glutamine,
100 U/ml penicillin G, 100 mg/ml streptomycin (Gibco, Carlsbad, CA,
USA; cat. no. 10378-016) and recombinant human granulocyte-
macrophage colony stimulating factor (GM-CSF) plus interleukin 4
(IL-4) (50 ng/ml and 20 ng/ml respectively, (Miltenyi Biotec, Auburn,
CA, USA; cat. no. 130-095-372 and cat.no. 130-093-917). Monocytes
were exposed to sera of HCV-infected patients or healthy donors for
60 min at 370C and then cultured in the differentiation cocktail in the
presence of 20% of the same sera. In some experiments monocytes
were differentiated in the presence of baﬁlomycin A1 (20 nM) and
rapamycin (1 μM) or cathepsin inhibitors pepstatin A (10 μM) and in-
hibitor III (20 μM).
2.4. Analysis of DC phenotype by ﬂow cytometry (FACS analysis)
The phenotype of DCs was monitored by staining with phycoeritrin
(PE)-conjugated anti CD1a for 30 min at 4 °C and analyzed by a
cytoﬂuorimeter EPICS XL Coulter (Hialeah, FL). DCs were gated
Fig. 1.HumanHCV-positive sera block autophagy in differentiatingmonocytes. A) Expres-
sion levels of LC3I/II, p62 and HCV-core protein were analyzed by western blot of equal
amount of total cell extracts of monocytes undergoing A) 24 h and B) 5 days of in-vitro dif-
ferentiation, induced by GM-CSF and IL-4 in the presence of healthy donor (HCV−) or
HCV-positive sera (HCV+). Anti-actin was used as protein loading control. C) Western
blot analysis of LC3I/II expression level of monocytes cultured in the presence of healthy
donor (HCV−), HCV-positive (HCV+), HCV-positive ultraﬁltered (HCV ﬁltered) sera
and baﬁlomycin (baf) is reported. GAPDH was used as protein loading control. A densito-
metric analysis based on the ratio LC3 II/GAPDH is reported and a representative experi-
ment out of three is shown.
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were included and 5.000 viable DCs were acquired for each sample.
2.5. Western blot analysis
Monocytes differentiated in the presence of HCV-containing sera or
healthy donor sera (10 × 105) were lysed in a modiﬁed RIPA buffer
containing 150 mM NaCl, 1% NP-40, 50 mM Tris–HCl (pH 8), 0.5%
deoxycholic acid, 0.1% SDS, 1% Triton X-100, protease and phosphatase
inhibitors. The lysates were prepared according to the manufacturer's
instructions (Life Technologies), subjected to electrophoresis on 4–
12% NuPage Bis–Tris gels (Life Technologies, Carlsbad, CA; cod.
no. NO0322BOX) and transferred to PVDF membranes (Millipore Cor-
poration, Billerica, MA, USA; cat. no. IPVH00010). The membranes
were blocked for 1 h in phosphate buffered saline (PBS) (Sigma,
St. Louis, USA; cat. no. D8537), blocking solution, containing 3% bovine
serum albumine (BSA) (Sigma, St. Louis, USA; cat. no. A4503), and
0.1% Tween 20 (Sigma, St. Louis, USA; cat. no. P5927) and then incubat-
ed with a primary antibody overnight at 4 °C. The membranes were
washed 5 min for three times in the washing solution (PBS and 0.1%
Tween 20) and incubated for 45 min with appropriate horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnolo-
gy, Europe; cat. no. sc-2004, sc-2768, sc-2005). The membranes were
washed as described before and the blots were developed using ECL
blotting substrate (Thermo Scientiﬁc, Rockford, USA; cat. no. 32209).
2.6. Red-BSA assay
Monocytes differentiated for 24 h in the presence of healthy donor
or HCV-infected patients were treated with DQTM Red BSA (DQ-BSA)
(Molecular Probes) (Life Technologies, Monza, Italy, Europe; cat. no.
D-12051) (20 mg/ml) for 15 min at 370C, washed twice and kept at
370C for 2 h. Cells were then analyzed using an Apotome Axio Observer
Z1 inverted microscope (Zeiss, Oberkochen, Germany), equipped with
an AxioCamMRM Rev.3 at 40× magniﬁcation.
2.7. Cell viability analysis
Monocytes, differentiated for 5 days in the presence of HCV-negative
or HCV-positive sera, were collected and counted by trypan-blue exclu-
sion assay using a hemocytometer. Each experiment was performed in
triplicate.
2.8. Statistical analysis
All experimental results, unless differently indicated, were
expressed as the arithmetic mean and standard deviation (SD) of mea-
surements. Student's t-test was used for statistical signiﬁcance of the
differences between treatment groups. Statistical analysis was per-
formed using analysis of variance at 5% (p b 0.05) or 1% (p b 0.01).
3. Results
3.1. HCV-positive sera block autophagy during monocyte differentiation
CD14+ monocytes, isolated from healthy donors, differentiate in-
vitro into DCs when cultured in the presence of GM-CSF and IL-4, for 5
days [27]. It has been reported that GM-CSF, contained in the differenti-
ation cocktail, induces autophagy and that the autophagic process is es-
sential for the in-vitro monocyte differentiation [19]. Here we ﬁrst
investigated whether the HCV-positive sera could inﬂuence autophagy
in monocytes differentiating into DCs. At this aim, we exposed human
monocytes to sera derived from HCV-infected patients or from healthy
donors (see Materials and methods) and then cultured them in com-
plete medium, containing GM-CSF and IL-4, in the presence of 20% of
the same HCV-positive or HCV-negative serum. After 24 h or after 5days of in-vitro differentiation, the two main autophagic markers, LC3
I/II and p62, were analyzed by western blot. We observed an increase
of LC3 II level in monocytes exposed to HCV-containing serum in com-
parison to the same cells exposed to healthy donor serum (Fig. 1A and
B), indicating an impact of HCV-positive serum on monocytes' autoph-
agy. Since the LC3 II increase, by itself, does not discriminate between
autophagic induction and/or autophagic blockage at the late steps, we
analyzed p62, which is a read out of the bona ﬁde autophagic process.
The results show a strong accumulation of p62 protein levels in the
monocytes cultured in the presence of HCV-positive serum for 24 h
and after 5 days of in-vitro culture (Fig. 1A and B), in comparison to
the same cells exposed to the healthy donor-serum, suggesting that a
block of the autophagic ﬂux was occurring in these cells. After 24 h of
viral-exposure, HCV core protein was transiently detected, by western
blot analysis, in differentiating monocytes exposed to HCV-positive
serum and it was no more visible after 5 days culture (Fig. 1 A and B).
A possible explanation of HCV core disappearance might be that HCV
binds or enters in differentiating monocytes but it does not efﬁciently
replicate in them, as occurs in differentiated DCs or that the HCV-
infected monocytes do not survive after 5 days of culture (see below),
according to previously reported studies [28,29]. Then, to clarify wheth-
er the effects on autophagy were mediated by the virus itself or by the
molecules, such as cytokines, possibly present in HCV-positive sera,
we ultraﬁltered the HCV-positive sera through 30 kmembrane columns
(HCV + ﬁltered), to remove the viral particles. The results obtained
show that the increase of LC3 II level in monocytes exposed to HCV-
containing serum was efﬁciently reduced by removing the viral parti-
cles from the sera (Fig. 1C), highlighting the role of HCV itself inmediat-
ing the autophagy block in differentiatingmonocytes. Finally, to conﬁrm
that autophagy was blocked at late steps by HCV-containing serum, we
compared its effect with the effect mediated by baﬁlomycin (baf),
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agy. The results obtained showed that LC3 II level increased both in
monocytes cultured in the presence of baf or in the presence of HCV-
positive sera (Fig. 1C).
3.2. HCV reduces the expression level of cathepsins B and D in differentiat-
ing monocytes
We next investigated which molecular mechanism/s could underlie
the autophagic block at late steps mediated by HCV containing sera in
differentiating monocytes. We analyzed the expression level of cathep-
sins since thesemolecules play amajor role in thedegradation of the au-
tophagic cargo and have been previously shown to inﬂuence the bona
ﬁde outcome of the autophagic process [23]. Moreover, it has been pre-
viously reported that HCV reduces the level of cathepsin B or S in other
cell types [20,30]. As shown in Fig. 2A, the expression level of cysteine
cathepsin B was strongly reduced in differentiatingmonocytes exposed
to HCV-containing serum while cathepsin S was slightly affected
(Fig. 2A). Cathepsin B plays an important role in the degradative steps
of autophagy, while cathepsin S is involved in the MHC presentation,
one of the most important functions of these cells [31]. Finally we eval-
uated the expression level of the aspartyl cathepsin D, which, together
with cathepsin B, represents the most important cathepsin involved in
the degradative process of autophagy inmonocytes. These cells, indeed,
do not express cathepsin L, the other protease with a major role in such
process [32]. We found that cathepsin D expression was also strongly
reduced by serum of HCV-infected patients in differentiating mono-
cytes, after 24 h of in-vitro culture (Fig. 2B). To evaluate whether the re-
duced expression level of cathepsins in monocytes cultured in the
presence of HCV-containing serawas also accompanied by a reduced ly-
sosomal proteolytic activity, we treated differentiating monocytes with
DQTM Red (DQ-BSA). This molecule is a derivative of bovine serum al-
bumin that is labeled with self-quenched red ﬂuorescent dye and can
be dequenched by proteases, such as cathepsins, present in the lyso-
somes [23,33]. As in other studies, where the cathepsin content wasFig. 2. Human HCV-positive sera reduce cathepsin expression in differentiating mono-
cytes. A)Western blot analyses showing the expression levels of cathepsin B, S and B) ca-
thepsinD inmonocytes differentiated for 24h in thepresence ofHCV-negative (HCV−) or
HCV-positive (HCV+) sera. β-actin was used as protein loading control. A densitometric
analysis based on the ratio cathepsins/actin is reported and a representative experiment
out of three is shown. C) Fluorescence analysis of human primary monocytes differentiat-
ed for 24h in the presenceofHCV-negative (HCV−) orHCV-positive (HCV+) sera treated
with DQ-BSA to evaluate the proteolitic activity. A representative experiment out of three
is shown. Bars = 10 μm.reduced [23], we found that the red staining of DQ-BSA was less bright
in monocytes cultured in the presence of HCV-containing sera for 24 h,
in comparison to those cultured in the presence of healthy donors' sera
(Fig. 2C), indicating a reduced proteolytic activity, concomitantly with
the reduced cathepsin expression observed by western blot analysis
(Fig. 2A and B). Altogether, these data indicate that HCV-containing
sera reduced the expression level of cathepsins and proteolytic activity
in differentiating monocytes.
3.3. The HCV-mediated cathepsin reduction results in an impairment of
monocyte differentiation into DCs
We showed above that HCV-containing sera impaired autophagy
and lysosomal activity during monocyte differentiation. Since autopha-
gy, induced in monocytes by GM-CSF contained in the differentiating
cocktail, seems to be essential for their in-vitro differentiation into DCs
[19], we investigated whether the autophagic block, induced in mono-
cytes by sera of HCV infected patients, could impair their differentiation
into DCs. At this aim, we analyzed the surface expression of CD1a, a
marker typically expressed by differentiated DCs. As control, to conﬁrm
that autophagy modulation can affect the monocyte differentiation, we
included the autophagic blocker baﬁlomycin A1 (baf) and the autopha-
gy inducer, rapamycin (rapa). As shown in Fig. 3A, after 3 days of cul-
ture, the expression level of CD1a was reduced in DCs exposed to
HCV-containing serum (HCV+) in comparison to DCs differentiated in
the presence of differentiation cocktail only (control). Similar results
were obtained in the presence of the autophagy inhibitor baf and
CD1a expression was slightly affected in DCs exposed to healthy
donor serum (HCV−) (Fig. 3A). On the other hand, in the presence of
rapa, after only 3 days of in-vitro culture, CD1a expression reached the
level of completely differentiated cells, which is usually achieved by
DCs after 5 days (Fig. 3A). These data are in agreement with previous
studies indicating that the autophagic process is essential for monocyte
differentiation and suggest that its block by HCV-containing sera, simi-
larly to pharmacological autophagy inhibitors, leads to a reduction of
DC formation. After 5 days of in-vitro culture, when the differentiating
process is complete, CD1a surface expression was again evaluated in
DCs. We found that CD1a expression was still reduced in DCs cultured
in the presence of HCV-positive serum or of the autophagic blocker
baf, compared to the healthy donor serum (HCV−), either in terms of
percentage of positive cells or mean ﬂuorescence intensity (MFI)
(Fig. 3B and C). Of note, when the viral particles were removed through
ultraﬁltration, HCV-depleted serum (HCV ﬁltered) no longer affected
monocyte differentiation, in a way similar to the healthy donor serum
(Fig. 3B and C) and in agreement with the little inﬂuence on autophagy
seen in Fig. 1C. These data highlight the role of HCV particles in both the
impairment of monocyte differentiation and in the block of the mono-
cyte autophagy.
Since the autophagic block and the impairment of DC formation
mediated by HCV may occur through the reduction of cathepsin B and
D expression, we next analyzed the effect of both cathepsin D and B in-
hibitors (pepstatin A and inhibitor III, respectively) on monocyte differ-
entiation into DCs. The results indicate that cathepsin B and D inhibitors
impaired DC differentiation (Fig. 4A and B), suggesting that cathepsins
are required for monocyte differentiation. Cathepsin reduction by
HCV-positive sera could be the mechanism underlying the impairment
of monocyte differentiation.
3.4. The block of autophagy by HCV-positive sera reduces cell survival in
differentiating monocytes
To evaluate if the autophagic block caused by HCV-positive sera
would also affect cell survival in differentiating monocytes, we per-
formed a trypan-blue exclusion viability assay. The results, shown in
Fig. 5A, indicate that about 90% of cell survival observed in the presence
of healthy donor sera signiﬁcantly dropped down to 50% in the presence
Fig. 3. Human HCV-positive sera impair monocyte differentiation into DCs. A) FACS analysis showing the CD1a expression in human primary monocytes differentiated for 3 days in the
differentiation cocktail containing GM-CSF and IL-4 in the absence (control) or in the presence of HCV-negative (HCV−) or HCV-positive sera (HCV+) or ultraﬁltered HCV-positive
serum (HCV ﬁltered) or baﬁlomycin (baf) or rapamycin (rapa). Histograms represent the mean ± SD of three independent experiments. B) FACS analysis showing the CD1a expression
in DCs differentiated for 5 days in the differentiation cocktail in the absence (control) or in the presence of HCV-negative (HCV−) or HCV-positive sera (HCV+) or ultraﬁltered HCV-
positive (HCV ﬁltered) sera or baﬁlomycin (baf). The results shown are percentage of CD1a positive cells ± SD of three independent experiments. C) FACS analysis, as staining proﬁles,
of a representative experiment showing the percentage of CD1a and mean ﬂuorescence intensity (MFI) of monocytes differentiated in the presence of HCV-negative (HCV−) or HCV-
positive (HCV+) or ultraﬁltered HCV-positive (HCV ﬁltered) sera or baﬁlomycin (baf) over control differentiated cells.
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ferentiated in the GM-CSF and IL-4 differentiation cocktail. To further
demonstrate the induction of cell death by HCV-containing sera, PARP
cleavage was evaluated by western blot analysis. The results show a
strong PARP cleavage in monocytes differentiated in the presence of
HCV-positive sera compared to monocytes cultured in the presence of
healthy donor sera (Fig. 5B). These data suggest that the autophagicblock mediated by HCV, aside from hampering monocyte differentia-
tion, also induced cell death in these cells.
4. Discussion
HCV infection becomes chronic in about 80% of patients, indicating
that the virus is able to circumvent the immune response [24]. DCs
Fig. 4. Cathepsin D and B inhibition impairs monocyte differentiation into DCs. FACS analysis of CD1a expression in DCs differentiated for 5 days in the presence or in the absence of ca-
thepsin D (pepstatin A) and cathepsin B inhibitor (inhibitor III). A) Mean ± SD of three independent experiments is reported and B) data from a representative experiment, as staining
proﬁles, showing CD1a expression of DCs differentiated in the presence of the combination of pepstatin A and inhibitor III over control differentiated cells.
1353M. Granato et al. / Biochimica et Biophysica Acta 1843 (2014) 1348–1355have a central role in both innate and adaptive immunity, being able to
sense pathogens, phagocyte them and present their processed peptides
to T cells, initiating a speciﬁc immune response. The DC functional im-
pairment, frequently observed in patients affected by chronic hepatitis
C, could be a possible underlying mechanism of such immune dysfunc-
tion [24]. Moreover, it has been shown that DCs derived from patients
with HCV persistent infection stimulate the proliferation of regulatory
T cells (Tregs), which further impairs the HCV-speciﬁc T cell response
[34] and that HCV core protein may play a major role in the develop-
ment of IL-10-producing Tregs [35]. The interference with DC develop-
ment and functions, in-vivo and in-vitro, represents a common strategy
utilized by viruses, belonging to different families, to escape from im-
mune control [36–38]. In-vitro studies on HCV have reported that core
and NS3 recombinant proteins are able to inhibit the in-vitro differenti-
ation ofmonocytes intoDCs and also thatHCV repliconmodel, JFH-1, in-
terferes with DCmaturation [39,40]. However extensive immunological
in-vitro studies with whole virus have been hampered by the absence
of a cell culture system for HCV and most of the studies use the
replicon viral models that are not generally able to infect immune
cells [22]. In-vitro monocyte infection can be achieved with the virus
isolated from plasma or serum of HCV-infected patients and it is
known that monocytes [3,41], DC macrophages, and B and T lympho-
cytes harbor HCV infection in-vivo [8]. In this study we used naturalFig. 5.HumanHCV-positive sera reduce the human primarymonocytes survival. A) DCs, differe
positive (HCV+) sera,were counted by trypan blue exclusion in comparison to the control DCs
of cell survival and p value of three different experiments is reported. B) Western blot analysis
ferentiated in the presence of healthy donor (HCV−) or HCV-positive (HCV+) sera. A represeHCV from sera of HCV-infected patients to reproduce more closely the
interplay between monocytes and the virus that occurs in-vivo, in the
course of natural infection. We found that, in the presence of HCV-
containing sera, the autophagic ﬂux, essential for monocyte differentia-
tion, was blocked and that this blockage resulted in an impairment of
the monocyte differentiation into DCs. Similar effects were obtained
by using baf, a well known autophagic blocker, conﬁrming that a com-
plete autophagic process is required for DC formation. Of note, when
sera of HCV-infected patients underwent ultraﬁltration to remove HCV
particles, DC differentiation was no longer affected, indicating that
HCV present in infected sera was playing the major role in inhibiting
DC formation. Interestingly, we found that the differentiating mono-
cytes exposed to HCV-containing sera, transiently expressed HCV core
protein which, according to a previous study [35], could play an impor-
tant role in the immune suppression. Since it has been reported that
monocytes derived from HCV-positive patients remain HCV-infected
only for 1 day in culture because cell death occurs selectively in the in-
fected monocytes [1], we speculate that this could be the reason for the
disappearance of HCV core expression in differentiating monocytes
after 5 days of in-vitro culture (Fig. 1B) and for the increased cell
death observed in these cells (Fig. 5) [28]. HCV replicon models and
hepatoma cell lines have been previously used to investigate the role
of autophagy in the pathogenesis of HCV-induced hepatitis or in type Intiated for 5 dayswith GM-CSF and IL-4 in the presence of healthy donor (HCV−) or HCV-
differentiated in the cocktail containing GM-CSF and IL-4 in the absence of sera.Mean± SD
with anti-cleaved PARP (poly-ADP-ribose polymerase) p85 fragment antibody of DCs dif-
ntative experiment is shown. Lamin B was used as protein loading control.
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sera blocked the autophagic ﬂux in differentiating monocytes, in corre-
lation with a reduction of cathepsin D and B expression and with a de-
creased proteolytic activity.
Cathepsins B and D are the cysteine and aspartyl cathepsins funda-
mental for the degradation of the autophagic cargo in the lysosomal
compartment [23], while the cysteine cathepsin S, also partially reduced
by sera of HCV-infected patients, could interfere with the invariant
chain (Ii) cleavage, Major Histocompatibility Complex (MHC) class II
maturation and surface expression and ﬁnally with antigen presenta-
tion [31]. In a previous study, it has been reported that HCV, and in par-
ticular its core andNS5a proteins, reduced cathepsin S expression and as
a consequence the Ii resulted to be more expressed on the cell surface,
concomitantly with a reduction of mature MHC class II [30]. Our results
suggest that the cathepsin reduction in DCsmay represent an important
HCV strategy to escape from the immune control. Indeed, by reducing
cathepsins B and D, HCV blocked the autophagic process and impaired
DC differentiation. The autophagic block could further promote the
viral immune escape by interfering with the viral degradation in the ly-
sosomes and MHC class II antigen presentation. The latter could be also
impaired by HCV-mediated reduction of cathepsin S. It will be interest-
ing to investigate how HCV-containing human sera would affect au-
tophagy and differentiation of monocytes in-vivo, using the recently
developed humanized mouse model AFC8-hu HSC/Hep [43]. These
mice, containing human immune system and liver cells, could be useful
to evaluate the impact of HCV-mediated DC functional impairment on
the liver diseases. Moreover it will be interesting to analyze if the re-
cently discovered anti-HCVdrugs could inﬂuence autophagy in immune
as well as in liver cells.
5. Conclusions
In summary, this study showing that HCV blocks autophagy and
monocyte differentiation into DC unveils a new strategy utilized by
HCV to ensure its persistence in the host and to promote the onset of
chronic virus-associated diseases. The understanding of the HCV-
mediated effects on the immune system is essential to be able to design
new immunotherapies effective against HCV.
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